Home » Archive

News

News, Syndication, Xconomy »

The Innovation Imperative: How Corporations and Nations Can Survive the Tsunami of Global Competition and Thrive

Posted by Mary Canady September 3rd, 2010 .
No Comments
Government leaders in Europe and North America are seeking to formulate enlightened, effective policies to create the necessary ecosystems and help their corporations respond to threats of loss of...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Orexigen Nabs $1B Deal With Takeda to Market Obesity Drug, Shares Climb

Posted by Mary Canady September 2nd, 2010 .
No Comments
San Diego-based Orexigen Therapeutics has found a partner to help it compete in the growing market for drugs to combat obesity. It’s Japan-based Takeda Pharmaceutical. Under the terms of the...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Otonomy Gets $38.5M, Avalon Helps Restart Drug for Age-Related Blindness, Accumetrics Heads Toward Profitability, & More San Diego Life Sciences News

Posted by Mary Canady September 2nd, 2010 .
No Comments
The life sciences news over the past week was almost all about deals. Money came out of INC Research, a contract research organization in North Carolina that was founded in San Diego. Money went into...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Accumetrics Adds $7 Million in Venture Funding, Plans to Reach Profitability

Posted by Mary Canady September 1st, 2010 .
No Comments
San Diego-based Accumetrics says today it has raised an additional $7 million as part of a Series E venture round that was announced last October, when the biomedical diagnostics company raised about...

[[Click headline to continue reading.]] More...

BioSpace, News, Syndication »

Genzyme Corporation And Isis Pharmaceuticals, Inc. Release: Data from Mipomersen Phase 3 Trial in heFH Patients Meets Primary Endpoint with 28 Percent LDL-C Reduction

Posted by BioSpace.com Featured News September 1st, 2010 .
No Comments
CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ - News) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS - News) announced that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented today at the European Society of Cardiologys Congress 2010 in Stockholm, Sweden. The study met its primary endpoint with... More...

BioSpace, News, Syndication »

Takeda Pharmaceutical Co. Ltd. And Orexigen Therapeutics, Inc. Sign $1 Billion Obesity Pact

Posted by BioSpace.com Featured News September 1st, 2010 .
No Comments

SAN DIEGO and OSAKA, Japan, Sept. 2 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) and Takeda Pharmaceutical Company Limited (TSE: 4502), today announced that they have entered into an exclusive partnership to develop and commercialize Contrave (naltrexone... More...

BioSpace, News, Syndication »

Cebix Raises $16M From Investors

Posted by BioSpace.com Featured News September 1st, 2010 .
No Comments
Xconomy -- San Diego-based Cebix, which is developing a replacement therapy based on human proinsulin C-peptide as a supplemental treatment for complications from type 1 diabetes, has raised $16 million over the past 14 months, according to a form filed with regulators Monday. The form amends a regulatory filing that Cebix submitted in June, 2009, which disclosed it had raised almost $2.3 million... More...

BioSpace, News, Syndication »

MediciNova, Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference

Posted by BioSpace.com Featured News September 1st, 2010 .
No Comments
SAN DIEGO, Sept. 2, 2010 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that Shintaro Asako, Chief Financial Officer of MediciNova, will present a company overview at the Rodman and Renshaw Annual Global Investment Conference... More...

BioSpace, News, Syndication »

Optimer Pharmaceuticals, Inc. Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming Annual Meeting

Posted by BioSpace.com Featured News September 1st, 2010 .
No Comments

SAN DIEGO, Sept. 2 /PRNewswire/ --Results from studies related to Optimer Pharmaceutocation">Boston on September 12-15, 2010.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO... More...

BioSpace, News, Syndication »

Halozyme Therapeutics, Inc. Begins Phase 2 Clinical Trials With Insulin Analogs Lispro and Aspart With rHuPH20 in Type 1 and Type 2 Diabetes

Posted by BioSpace.com Featured News September 1st, 2010 .
No Comments

SAN DIEGO, Sept. 2 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active... More...

Next Page »